IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

In a separation agreement dated June 14, 2019, William M. Moore agreed to resign as Director of Iridex Corporation (the “Company”), effective as of June 22, 2019. Mr. Moore is not resigning due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.  The effective date of the separation agreement was June 22, 2019.

Item 9.01.Financial Statements and Exhibits.

IRIDEX CORP Exhibit
EX-10.1 2 irix-ex101_7.htm EX-10.1 irix-ex101_7.htm Exhibit 10.1   SEPARATION AGREEMENT AND GENERAL RELEASE   This Separation Agreement and General Release (hereinafter referred to as “Agreement”) is made and entered into by and between William M. Moore (hereinafter referred to as “Executive”) and Iridex Corporation (hereinafter referred to as “Iridex” or “Company”).   In consideration of the mutual covenants and promises herein contained and other good and valuable consideration,…
To view the full exhibit click here

About IRIDEX CORPORATION (NASDAQ:IRIX)

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

An ad to help with our costs